Condition
    Preliminary
    Effectiveness 2/5

    Magnesium for Chronic Pain

    Mechanistically interesting for sensitised pain, with clinical evidence that has not yet delivered.

    Overview

    Mechanistically interesting for sensitised pain, with clinical evidence that has not yet delivered.

    Verdict

    Insufficient evidence

    NMDA receptor blockade gives a credible mechanism for central sensitisation, but oral trials in chronic pain are small and inconsistent.

    How It Works

    Magnesium is a voltage-dependent blocker of the NMDA receptor channel, the same receptor implicated in wind-up and central sensitisation in the dorsal horn. Low magnesium removes this block, increasing excitatory glutamatergic transmission and potentially lowering pain thresholds.

    Dosing & Protocol

    Typical dose

    Recommended dose
    200-400 mg daily of elemental magnesium as glycinate or citrate, taken in the evening
    Expected timeframe
    4-8 weeks for any perceptible change

    Protocol

    form
    Magnesium glycinate
    duration
    8 weeks; stop if unchanged
    co factor
    Evidence is insufficient: intravenous magnesium has shown short-lived analgesia in surgical and neuropathic settings, but oral magnesium at 300-400 mg daily has not reduced chronic pain scores in controlled trials. Do not build a pain plan around it.
    titration
    Up to 350 mg daily
    starting dose
    200 mg elemental magnesium with food, if trialled at all

    Evidence

    What the studies say

    The strongest data are perioperative and intravenous: meta-analyses of intravenous magnesium during surgery show reduced postoperative opioid consumption and pain scores, which supports the NMDA mechanism in humans. Translating this to oral supplementation in chronic pain is where the evidence weakens. Small randomised trials in fibromyalgia using magnesium citrate or malate report modest improvements in tender point counts and pain scores, but sample sizes are under 100 and blinding is often imperfect. Trials in neuropathic pain are similarly inconclusive. Oral bioavailability and the difficulty of raising central nervous system magnesium concentrations are plausible reasons the intravenous findings do not transfer. Magnesium remains a low-risk adjunct, with a genuine benefit for the muscle cramps and sleep disruption that commonly accompany chronic pain, rather than a demonstrated analgesic.

    No studies are yet linked to both Magnesium and Chronic Pain.

    Safety

    Caveats

    Doses above 400 mg commonly cause diarrhoea. Accumulates dangerously in kidney impairment. Reduces absorption of tetracycline and quinolone antibiotics and of bisphosphonates if taken together.

    Less likely to help if

    People with adequate magnesium status and predominantly peripheral nociceptive pain.

    Medical Disclaimer

    The information provided on this website is for educational and informational purposes only and is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any supplement regimen.

    Individual results may vary. The statements on this website have not been evaluated by the Food and Drug Administration. Products and information are not intended to diagnose, treat, cure, or prevent any disease.